Advancing cancer therapy: new frontiers in targeting DNA damage response
Frontiers in Pharmacology · 20.09.2024 · 15
DOI: 10.3389/fphar.2024.1474337 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.09.2024. Verfasst von Jiekun Qian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Genomic instability is a core characteristic of cancer, often stemming from defects in DNA damage response (DDR) or increased replication stress. DDR defects can lead to significant genetic alterations, including changes in gene copy numbers, gene rearrangements, and mutations, which accumulate over time and drive the clonal evolution of cancer cells. However, these vulnerabilities also present opportunities for targeted therapies that exploit DDR deficiencies, potentially improving treatment efficacy and patient outcomes. The development of PARP inhibitors like Olaparib has significantly improved the treatment of cancers with DDR defects (e.g., BRCA1 or BRCA2 mutations) based on synthetic lethality. This achievement has spurred further research into identifying additional therapeutic targets within the DDR pathway. Recent progress includes the development of inhibitors targeting other key DDR components such as DNA-PK, ATM, ATR, Chk1, Chk2, and Wee1 kinases. Current research is focused on optimizing these therapies by developing predictive biomarkers for treatment response, analyzing mechanisms of resistance (both intrinsic and acquired), and exploring the potential for combining DDR-targeted therapies with chemotherapy, radiotherapy, and immunotherapy. This article provides an overview of the latest advancements in targeted anti-tumor therapies based on DDR and their implications for future cancer treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
- Fujian Key Laboratory of Cardiothoracic Surgery, Fujian Medical University, Fuzhou, China.
- Clinical Research Center for Thoracic Tumors of Fujian Province, Fuzhou, China.
- Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Cardiac Medical Center Nursing, Fujian Medical University Union Hospital, Fuzhou, China.
Zitieren
APA
Qian, J., Liao, G., Chen, M., Peng, R. W., Yan, X., Du, J., Huang, R., Pan, M., Lin, Y., Gong, X., Xu, G., Zheng, B., Chen, C., & Yang, Z. (2024). Advancing cancer therapy: new frontiers in targeting DNA damage response. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1474337
Vancouver
Qian J, Liao G, Chen M, Peng RW, Yan X, Du J, et al. Advancing cancer therapy: new frontiers in targeting DNA damage response. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1474337
BibTeX
@article{Qian2024,
author = {Qian, Jiekun and Liao, Guoliang and Chen, Maohui and Peng, Ren-Wang and Yan, Xin and Du, Jianting and Huang, Renjie and Pan, Maojie and Lin, Yuxing and Gong, Xian and Xu, Guobing and Zheng, Bin and Chen, Chun and Yang, Zhang},
title = {Advancing cancer therapy: new frontiers in targeting DNA damage response},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1474337}
}
EUVIMED